Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Oi Chung

Physician Assistant Monterey Park, CA Physician Assistant

NPI 1104085893 CMS profile 10440785

525 N Garfield Ave, Monterey Park, CA 91754

Open in the dashboard

General payments

$5,075

150 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Oi Chung of Monterey Park, CA is reported in the CMS Open Payments database as having received $5,075 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $267 12
2024 General $1,251 33
2023 General $579 25
2022 General $2,002 49
2021 General $976 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Oi Chung
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Oi Chung were reported at $267. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Oi Chung Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $976 $132 $37–$438 $132
2022 $2,002 $155 $48–$522 $149
2023 $579 $167 $52–$557 $160
2024 $1,251 $178 $55–$600 $164
2025 $267 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $1,880 66 payments
  2. AbbVie, Inc. $1,665 55 payments
  3. Eko Devices, Inc. $399 1 payment
  4. Phathom Pharmaceuticals, Inc. $287 10 payments
  5. AstraZeneca Pharmaceuticals LP $250 2 payments
  6. Madrigal Pharmaceuticals $245 5 payments
  7. RedHill Biopharma Inc. $140 2 payments
  8. Ardelyx, Inc. $113 4 payments
  9. Braintree Laboratories, Inc. $35 2 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $23 1 payment
  11. Other $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,658 148 payments
  2. Long term medical supply or device loan $399 1 payment
  3. Gift $18 1 payment
Products named General payments · program years 2021–2025
  1. RINVOQ $657 23 payments
  2. SKYRIZI $599 16 payments
  3. Vemlidy $400 3 payments
  4. HUMIRA $384 15 payments
  5. Epclusa $321 3 payments
  6. VOQUEZNA $178 4 payments
  7. Talicia $140 2 payments
  8. Livdelzi $125 1 payment
  9. BREZTRI $125 1 payment
  10. FARXIGA $125 1 payment
  11. Other $712 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,003

Median for Physician Assistant: 241

Drug cost

$328,901

Median for Physician Assistant: $4,110

Branded share of claims

52.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vemlidy Tenofovir Alafenamide Brand 178 $252,872
Creon Lipase/Protease/Amylase Brand 17 $20,137
Zenpep Lipase/Protease/Amylase Brand 13 $17,916
Linzess Linaclotide Brand 15 $7,964
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 45 $7,656
Tenofovir Disoproxil Fumarate Generic 96 $5,513
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 71 $4,456
Ursodiol Generic 23 $2,519
Mesalamine Generic 17 $2,239
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 136 $2,153

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $234
$234 — —
Vemlidy
  • Gilead Sciences, Inc. $150
$150 178 —
Epclusa
  • Gilead Sciences, Inc. $125
$125 — —
Livdelzi
  • Gilead Sciences, Inc. $125
$125 — —
REZDIFFRA
  • Madrigal Pharmaceuticals $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record